Purpose of Review Atherosclerosis is an inflammatory disorder of the arterial wall, in which several players contribute to the onset and progression of the disease. Besides the well-established role of lipids, specifically cholesterol, and immune cell activation, new insights on the molecular mechanisms underlying the atherogenic process have emerged. Recent Findings Meta-inflammation, a condition of low-grade immune response caused by metabolic dysregulation, immunological memory of innate immune cells (referred to as "trained immunity"), cholesterol homeostasis in dendritic cells, and immunometabolism, i.e., the interplay between immunological and metabolic processes, have all emerged as new actors during atherogenesis. These observations reinforced the interest in directly targeting inflammation to reduce cardiovascular disease. Summary The novel acquisitions in pathophysiology of atherosclerosis reinforce the tight link between lipids, inflammation, and immune response, and support the benefit of targeting LDL-C as well as inflammation to decrease the CVD burden. How this will translate into the clinic will depend on the balance between costs (monoclonal antibodies either to PCSK9 or to IL-1ß), side effects (increased incidence of death due to infections for anti-IL-1ß antibody), and the benefits for patients at high CVD risk.
Atherosclerosis is a pathological condition characterized by a chronic, non-resolving low-grade inflammation within the arterial wall resulting from the accumulation of apoB-containing lipoproteins in sites where disturbed laminar flow is present [1] . This event triggers the recruitment of monocyte-macrophages, the most abundant immune cells present in atherosclerotic lesions, and cells of adaptive immune response such as T lymphocytes [1] .
Aim of this review is to discuss the emerging concepts in the field of immunity and atherosclerosis with a main focus on the interplay among lipids, cellular metabolic functions, and immune cell activation.
Cholesterol is an essential component of cellular membranes; lipid rafts are microdomains of the plasma membrane that are enriched in cholesterol and sphingolipids and serve as a platform in which proteins involved in signal transduction pathways transiently converge to trigger a cellular response [2] . In the context of atherosclerosis, lipid rafts are involved in the regulation of several processes including immune cell activation, inflammation, and proliferation of smooth muscle cells [2] . Alterations in the lipid composition of lipid rafts, and in particular in their cholesterol content, following the interaction with plasma lipoproteins, may lead to changes of lipid raft-dependent signaling. Such alterations include either cholesterol enrichment, triggered by the cholesterol transported in VLDL or LDL, or cholesterol depletion, induced by HDL [2] . LDL and oxidized LDL (including oxysterols) increase the formation of lipid rafts, which in turn support the translocation of proteins such as NADPH oxidase, transient receptor potential channel-1 (TRPC-1), or endothelial nitric oxide synthase, thus increasing oxidative stress, calcium-mediated apoptosis, secretion of pro-inflammatory cytokines, and inhibition of nitric oxide production [2] ; conversely, HDL-mediated-rafts reduction contributes to the maintenance of endothelial integrity [2] [3] [4] [5] . Lipid rafts also play a role in immune cell signaling by assisting the formation of immunological synapses, specialized membrane regions in which receptors essential for immune cell activity, including toll-like receptors (TLRs), T cell receptor (TCR), and B cell receptor (BCR) as well as major histocompatibility complex (MHC) molecules are located [6] . Studies on lymphocytes showed that the aggregation of membrane rafts facilitates cell signaling after TCR ligation [7] and that the accumulation of cholesterol in T cells from patients with systemic lupus erythematosus lowered the threshold for activation and TCR signaling leading to aberrant immune response [8] . Lipid rafts are also involved in antigen presentation by harboring MHCII and thus playing a key role in APC-mediated T cell activation and proliferation [9] . Disruption of these domains alters MHCII localization in raft microdomains and dramatically inhibits antigen presentation [10] ; similar findings were reported in macrophages where selective deficiency of ATP-binding cassette transporter A1 (ABCA1) leads to increased MyD88-dependent TLRs recruitment to lipid rafts [11] thus supporting a hyper-responsive phenotype to LPS challenge.
The imbalance between the rate of cholesterol uptake and the rate of cholesterol removal through efflux mechanisms in immune cells, however, does not only affect lipid rafts biology but also the accumulation of cholesteryl esters (CE) [12] . This may occur already in circulating mononuclear cells which become enriched in cholesterol when plasma levels of LDL are high and levels of HDL are low. Cholesterol-enriched monocytes are more likely to adhere to a damaged endothelium and migrate into the intima [13] [14] [15] , where they differentiate into macrophages. Indeed, lipid accumulation in monocytes, which has been observed in the postprandial phase and associated with increased activation in individuals with metabolic syndrome, may promote atherogenesis by facilitating their adhesion and transendothelial migration [16] . Here, macrophages may further take up modified lipoproteins through scavenger receptors and become foam cells. CE present in the core of lipoproteins, following cell uptake, are hydrolyzed to free cholesterol (FC). In the presence of excess FC, the cell compensates membrane damage and cytotoxicity by reducing cholesterol synthesis and uptake and increasing cholesterol efflux [17] . When these mechanisms fail, FC is re-esterified and stored in lipid droplets, which are metabolically active intracellular organelles composed by a hydrophobic core of neutral lipids surrounded by a phospholipid monolayer coated with specific proteins and involved in the development of atherosclerosis [17, 18] .
Although this mechanism is initially protective, the continuous accumulation of lipid droplets may shift macrophages to a long-term pro-inflammatory phenotype. This profile appears to be the consequence of the acquisition by innate immune cells of a memory which differs from what was observed in cells of the adaptive arm of the immune system [19, 20] . This phenomenon is referred to as "trained immunity" or innate immune memory (Fig. 1) . Trained immunity is based on epigenetic reprogramming, i.e., sustained changes in transcription programs following changes in chromatin organization, histone modifications, and persistence of microRNAs induced by the first exposure to the dangerous stimulus [19] . This leads to an increased pro-inflammatory response and may help to explain the basis of the well-established relationship between infection and atherosclerosis [21] . In the context of atherosclerosis, trained immunity may be induced also by non-microbial stimuli, such as oxidized LDL (OxLDL) or lipoprotein(a) [Lp(a)] [22, 23] . Experimental data suggest that a brief stimulation of monocytes with low concentrations of OxLDL (but not LDL) results in epigenetic histone modifications leading to increased production of pro-inflammatory cytokines and foam cell formation following re-stimulation [22] . The activation of trained immunity appears to be also related to Lp(a). Indeed, subjects with elevated Lp(a) levels not only exhibit increased arterial inflammation but also present monocytes which remain in a long-lasting primed state characterized by an enhanced capacity to adhere and transmigrate the endothelium and increased production of pro-inflammatory cytokine following TLR stimulation [23] . In addition, Lp(a) primes monocytes toward a responsive state, resulting in an increased production of pro-inflammatory cytokines upon restimulation [23] . Due to the short half-life of monocyte-macrophages, the concept of trained immunity implies that such epigenetic changes must be maintained by similar changes in hematopoietic precursor cells in the bone marrow [24] . Altogether, these observations suggest that, although trained immunity may represent a valuable way to protect the host against recurrent infections, it might contribute and even accelerate the development of atherosclerosis. Cholesterol crystals accumulation in the extracellular space may damage and activate intimal surface, thus resulting in the production of pro-inflammatory cytokines that promote the growth as well as atherosclerotic plaque destabilization [25] [26] [27] .
Emerging Immuno-Players in Atherosclerosis
At the molecular level, the enrichment of lipid rafts with cholesterol leads to the formation of cholesterol crystalline membrane domains which precedes the release of cholesterol crystal in the extracellular space [28] . Cholesterol crystals initiate inflammation via NLRP3 inflammasome activation, leading to the secretion of IL-1ß [29] . The inflammasome is a cytoplasmic complex, which is formed in response to damage/danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), and serves as a molecular platform for the activation of the cysteine protease caspase-1 [29] . Several types of inflammasome complexes have been reported, but only the activation of NLRP3 inflammasome and consequent inflammatory responses contributes to the progression of atherosclerosis [30] . Current data indicate that OxLDL could trigger inflammatory "priming" [31] , which is followed by cholesterol crystal-mediated activation of the inflammasome [32, 33] . Causality of this mechanism in atherogenesis has been demonstrated in LDL-R KO mice in which the deficiency of NRLP3 in bone marrow cells protects from the atherosclerotic plaque development [34] . Release of IL-1β and IL-18 pro-inflammatory cytokines following NRLP3 activation promotes atherosclerosis and the use of animal models have clearly demonstrated, with few exceptions [32, 35] , that their deficiency as well as deficiency of caspase-1 reduces the size of atherosclerotic lesions [36] [37] [38] [39] .
More recently, metabolically driven inflammation, known as meta-inflammation, was postulated to be critical in explaining the deep connection among obesity, diabetes, and atherosclerosis (Fig. 2) . [40] . Meta-inflammation is a chronic low-grade inflammation connecting alterations in systemic metabolism with the impairment in immune cells' metabolism and function [41] . The close relationship between metabolism and immuno-inflammation is further supported by the observation that NLRP3-deficient mice on a high-fat diet become insulin hypersensitive [42] , thus suggesting a closer connection between inflammasome and metabolism; in humans, increased levels of LDL-C induce pro-IL-1β production through TLRs [43] , and saturated fatty acids, such as palmitate and stearate, activate NLRP3 in primed macrophages in an ROS-and AMPK-dependent manner [44] . In mice, dyslipidemia induced by deficiency of key genes involved in cholesterol homeostasis, such as apolipoprotein E or ABCA1 or ABCG1, promotes myelopoiesis and extramedullary hematopoiesis, resulting in increased levels of circulating monocytes and inflammatory response, as a consequence of cholesterol enrichment in lipid rafts of immune cells [45] [46] [47] . These observations have driven the research toward the investigation of the impact of intracellular lipid alteration in immune cell function, a field known as immunometabolism [41] which shares molecular mechanisms of pathogenicity with cardiometabolic diseases, autoimmunity, and cancer. Lipid homeostasis is finely regulated by transcription factors, namely, liver X receptors (LXR) and sterol regulatory element-binding proteins (SREBP) which sense cholesterol and lipid concentration thus promoting lipid removal or biosynthetic pathways respectively [48] . This dichotomy has been widely investigated in macrophages where, following inflammation, de-novo lipogenesis is required to support inflammasome activation [49] , while later plays a key role in the resolution phase by producing Fig. 1 
anti-inflammatory fatty acids [50••] . Also, the activation of LXR is known to be anti-inflammatory as it represses TLRs 2-, 4-, and 9-dependent NF-кB activation via modulation of ABCA1-mediated cholesterol efflux, lipid raft enrichment, and reduces TLR localization in the membranes [51] . The notion that cholesterol is an important component of cell membrane and is essential for cell growth and proliferation [52] can likewise be applied to the adaptive immune response where lymphocytes undergo rapid expansion in response to antigenic challenge. Activation of LXR during T cell priming inhibits mitogen-driven expansion, while deficiency of LXRβ confers a proliferative advantage [53] ; on the contrary, SREBP signaling is critical for cholesterol synthesis and membrane biogenesis during blastogenesis and T cell expansion [54] . Once proliferated, immune cells migrate from the lymph nodes toward the inflamed tissues where they have to adapt to a different microenvironment with specific extracellular matrix, growth factors, oxygen, nutrients, and metabolites [55] . As an example, in a metabolically demanding environment such as tumors but also in atherosclerotic plaques, infiltrating immune cells change their immunometabolic settings and function [55] . Indeed, tissue/local enrichment of certain metabolites affects immune cell function as in the case of (i) lactic acid, which is produced during hypoxia at the site of inflammation and contribute disrupting T cell motility and reducing cytolytic function of CD8 T cells [56] or (ii) saturated fatty acids which are released by adipose tissue and differently affect differentiation and trafficking patterns of CD4 T cells [57•] .
Dendritic cells (DCs) play a key role in antigen processing and presentation and are therefore fundamental in connecting innate and adaptive immune response [58] . DCs migrate to lymphoid tissues to support the priming of selective antigenreactive T cell clones [59] and actively participate in all stages of atherogenesis from fatty streaks to mature lesion formation [60] . DCs undergo an extensive differentiation which relies also on changes in cellular metabolism. Lipid overload in DCs which are deficient in ABCA1/ABCG1 exacerbates autoimmune disease [12] and inflammasome activation [61••] , thus suggesting that cholesterol efflux pathways in these cells play a key role in the maintenance of immune tolerance. These findings suggest that the removal of cholesterol excess could be considered a therapeutic target to limit the immunoinflammatory response in the context of atherosclerosis and also of autoimmune diseases where HDL are less efficient in promoting cholesterol efflux [62, 63] . Stimulation of HDLdependent reverse cholesterol transport disrupts lipid rafts, attenuates antigen presentation in DCs [64] , and ameliorates autoimmune disease in mice [12] . Whether targeting cholesterol mobilization in immune cells will transfer in beneficial effect in the context of atherosclerosis, beyond increasing plasma HDL-C levels, remains to be addressed.
Targeting Inflammation to Reduce Cardiovascular Burden: a Lesson from the Clinical Trials
The key role of inflammation in atherosclerosis supports the hypothesis that targeting the immune-inflammatory response will have a beneficial impact on disease outcome.
Is There Scientific Evidence Supporting this Hypothesis?
Statins, by promoting LDL-R expression and LDL-C reduction, demonstrated a significant and robust benefit in terms of Fig. 2 Meta-inflammation balances functional and metabolic plasticity of immune cells. Obesity, diabetes, and atherosclerosis share a typical activation of the immuno-inflammatory response known as metainflammation, a chronic low-grade inflammation connecting alterations in systemic metabolism with the impairment in immune cells' cellular metabolism and function, i.e., immunometabolism. Meta-inflammation is associated with a shift of immune cell toward an activated phenotype associated with activation of the inflammasome, aberrant proliferation of lymphocytes, and enhanced stimulation of macrophages and dendritic cells cardiovascular risk reduction [65, 66] , an effect also ascribed to their ability to decrease circulating inflammatory markers such as CRP and to improve endothelial function and plaque burden [67] . Despite a large interindividual variability in LDL-C reductions following statin therapy [68] , an extensive meta-analysis of clinical trials with statins showed the tight dependence of CRP reduction on LDL-C reduction [69] . Studies with other lipid-lowering drugs in patients already presenting with baseline inflammed conditions showed that the beneficial effect of LDL-C-lowering therapies on systemic inflammatory status, as monitored by changes in CRP plasma levels, could be achieved, independently of the mechanism [70] . More importantly, Mendelian randomization studies have demonstrated that CRP is not a causal factor for atherosclerosis but, rather, an aspecific marker of systemic inflammation [71] [72] [73] [74] [75] . In many clinical trials with PCSK9 inhibitors, including the large outcome trial with evolocumab (FOURIER) [76] , baseline levels of CRP were below 2 mg/L [70] . In the FOURIER study, neither the treated arm nor the placebo arm experienced a reduction of CRP compared to baseline in spite of a substantial LDL-C reduction in the treated arm [76] . A similar trend was observed in many other trials where, in patients with CRP below 2 mg/L at baseline, LDL-C-lowering therapies, from statins to ezetimibe to anti-PCSK9 antibodies, did not affect CRP levels, perhaps because these patients did not present a relevant systemic inflammation [70] . Of note, even in patients with anti-PCSK9 antibodies, such as in the GLAGOV study, LDL-C reduction with anti-PCSK9 antibodies resulted in atherosclerotic plaque regression as determined by IVUS [77] . These observations strengthen the direct link between cholesterol and atherosclerosis and indicate that decreasing LDL-C levels is one of the key goals for improving cardiovascular outcome beyond tuning inflammation.
Do we have evidence that anti-inflammatory treatments improve cardiovascular outcome? While most of the studies with anti-inflammatory agents failed to show a relevant benefit in terms of cardiovascular risk reduction, the results from the CANTOS trial with a monoclonal antibody (canakinumab) targeting IL-1ß demonstrated a benefit on cardiovascular outcome [78••] . Patients with a previous myocardial infarction and elevated levels of highsensitivity C-reactive protein received one of three doses of canakinumab (50, 150 , and 300 mg) or placebo [78••] . The treatment with the antibody (150 mg) resulted in a significant lower incidence of the primary end point (a composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) vs placebo [78••] . The reduction was mainly driven by a reduction in the incidence of myocardial infarction [78••] . The benefit occurred in the absence of a difference in the LDL-C among groups. How can we reconcile these observations? As IL-1ß is downstream of the inflammasome activation driven by cholesterol, canakinumab targets a cholesterol-driven inflammatory response and, therefore, it is not surprisingly that a similar benefit in CVD risk reduction is achieved with anti-IL-1ß compared to LDL-C lowering.
Further, is targeting IL-1ß as safe as targeting the LDL-R pathway in terms of side effects? Data from a pooled analysis of the three doses of canakinumab used in the CANTOS trial showed a significant increase in the number of deaths from infection compared to those who received placebo [78••] . The investigators noted an intriguingly lower risk of cancer mortality with canakinumab than with placebo [79] , thus explaining the neutral effect on overall mortality.
These data support the interest for potential novel drugs targeting inflammation in atherosclerosis. In this context, the potential effects of dampening the immune response thus increasing the risk of infections should be carefully scrutinized. Moreover, given that available lipid-lowering therapies control vascular inflammation by reducing LDL levels without relevant effects on infections, clinical approaches should target lipids-lipoproteins-inflammation axis to achieve a cardiovascular benefit.
Current Scenario
Atherosclerosis is up-to-date recognized as a chronic inflammatory disease where lipids, inflammation, and immune response in concert contribute to the pathophysiology of the disease [80, 81] . IL-1ß has been proposed as a key player linking inflammation to atherogenesis and several other candidates which contribute to the inflammatory burden of atherosclerosis, such as IL-18, CD40/CD40L, and CCR2, have been identified [82] [83] [84] [85] [86] [87] [88] .
In humans, pharmacological targeting of IL-1ß was proven to reduce coronary artery disease [78••] ; however, other types of interventions, including the inhibition of lipoprotein-associated phospholipase A2 (LP-PLA2) with darapladib [89] , or TNF-alpha-mediated response with the anti-TNF-alpha strategies, have failed to reduce cardiovascular events in clinical trials [90] . These results suggest that inhibiting inflammation "tout court" does not always translate in a beneficial effect on CVD but rather appropriate pathways should be targeted from a clinical perspective. Moreover, a deep understanding of immuneinflammatory mechanisms playing a pathological role vs those which are bystanders of the inflammatory response is needed. Of note, the maintenance of a proper functional immune response is critical to minimize the risk of infection; a better identification of patients that will benefit most from IL-1ß inhibition should be performed also with the aim of minimizing the increased risk of death associated to sepsis in the CANTOS study.
Future Directions
The increased understanding of molecular basis of cardiovascular diseases is moving clinical practice toward the "precision medicine" shaped on patient with a unique signature of disease. Indeed, although statin decreases cholesterol levels and cardiovascular events, some patients do not fully benefit of the treatment, due to the persistence of a residual risk. Identification of selected biomarkers will help clinicians choose a personalized therapy based on patient's disease traits; this is the case of hs-CRP that, above 2 mg/L, which provides a solid rationale for the use of an anti-inflammatory strategy on top of lipidlowering drugs. On the other hand, anti-IL-1ß therapy does not fit all patients and indeed showed to reduce CHD only in those patients which demonstrated a significant reduction of CRP after three months on treatment [91] , further pointing to the need of biomarkers for tracking personalized therapy.
Conclusions
The CANTOS trial provides a reliable rationale for targeting inflammation beyond controlling plasma lipids. As cholesterol is known to promote plaque inflammation via inflammasome activation, it is conceivable that, by targeting IL-1ß on the top of lowering plasma lipids, the net effect of cholesterol in promoting atherosclerosis and CVD might be further dampened.
Whether similar conclusions will result from the CIRT trial, aimed at evaluating the cardiovascular benefit of low-dose methotrexate, a drug with systemic anti-inflammatory effects, in patients with prior myocardial infarction and type 2 diabetes or metabolic syndrome remains to be seen [92] but it will contribute to understanding whether we should "tailor" the anti-inflammatory strategy in the context of atherosclerosis or whether what counts is to limit inflammation.
